Print Friendly Page

Protocol No. S1500

Phase II

Age Group Adult

Scope National

Sponsor Type National

Title A Randomized Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [#749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

Applicable Disease Sites Kidney

Drugs Involved Cabozantinib; Savolitinib; XL184 (Cabozantinib); crizotinib; sunitinib

Status Open (affiliates only)

Participating Institutions Swedish American Hospital, Rockford